Bone Marrow Transplantation - Pipeline Review, H2

2015 Now Available at iData Insights

Bone Marrow Transplantation - Pipeline Review, H2 2015 Summary Global Markets Direct s, Bone
Marrow Transplantation - Pipeline Review, H2 2015, provides an overview of the Bone Marrow
Transplantations therapeutic pipeline. This report provides comprehensive information on the
therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic development for Bone Marrow
Transplantation and special features on late-stage and discontinued projects. Global Markets Directs
report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000
indications. The report is built using data and information sourced from Global Markets Directs
proprietary databases, Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party sources, put together by
Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation
following a stringent set of processes that ensures that all the profiles are updated with the latest set of
information. Additionally, processes including live news & deals tracking, browser based alert-box and
clinical trials registries tracking ensure that the most recent developments are captured on a real time
basis. The report enhances decision making capabilities and help to create effective counter strategies
to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed
or altered based on the availability and relevance of data for the indicated disease. Scope - The report
provides a snapshot of the global therapeutic landscape of Bone Marrow Transplantation - The report
reviews key pipeline products under drug profile section which includes, product description, MoA and
R&D brief, licensing and collaboration details & other developmental activities - The report reviews key
players involved in the therapeutics development for Bone Marrow Transplantation and enlists all their
major and minor projects - The report summarizes all the dormant and discontinued pipeline projects A review of the Bone Marrow Transplantation products under development by companies and
universities/research institutes based on information derived from company and industry-specific
sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and
combination therapy pipeline projects - Coverage of the Bone Marrow Transplantation pipeline on the
basis of target, MoA, route of administration and molecule type - Latest news and deals relating related
to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies - Identify emerging players with
potentially strong product portfolio and create effective counter-strategies to gain competitive
advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Bone
Marrow Transplantation - Plan mergers and acquisitions effectively by identifying key players of the
most promising pipeline - Devise corrective measures for pipeline projects by understanding Bone
Marrow Transplantation pipeline depth and focus of Indication therapeutics - Develop and design inlicensing and out-licensing strategies by identifying prospective partners with the most attractive
1

projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by
identifying discontinued projects and understanding the factors that drove them from pipeline.
with TOC
@ http://www.idatainsights.com/reports-landing-page.php?id=173356/bonemarrow-transplantation-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173356/bone-marrow-transplantation-pipeline-review-h2-2015

Table of Contents

Introduction 7
Global Markets Direct Report Coverage 7
Bone Marrow Transplantation Overview 8
Therapeutics Development 9
Pipeline Products for Bone Marrow Transplantation - Overview 9
Pipeline Products for Bone Marrow Transplantation - Comparative Analysis 10
Bone Marrow Transplantation - Therapeutics under Development by Companies 11
Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes 12
Bone Marrow Transplantation - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Bone Marrow Transplantation - Products under Development by Companies 16
Bone Marrow Transplantation - Products under Investigation by Universities/Institutes 17
Bone Marrow Transplantation - Companies Involved in Therapeutics Development 18
Anchor Therapeutics, Inc. 18
Boryung Pharmaceutical Co., Ltd. 19
Cleveland BioLabs, Inc. 20
Compugen Ltd. 21
Mesoblast Limited 22
Pluristem Therapeutics Inc. 23
2

Proteonomix, Inc. 24
Taiga Biotechnologies, Inc. 25
Targazyme, Inc. 26
Bone Marrow Transplantation - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
(filgrastim + plerixafor) - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ATI-2341 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BR-05001 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
CBLB-612 - Drug Profile 42
Product Description 42
Mechanism of Action 42

R&D Progress 42
Cell Therapy for Bone Marrow Transplantation - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CGEN-15001 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MPC-CBE - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
PLXR-18 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Protein for Bone Marrow Transplantation - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules to Inhibit Perforin for Bone Marrow Transplantation - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
TZ-101 - Drug Profile 53
Product Description 53
4

Mechanism of Action 53
R&D Progress 53
Bone Marrow Transplantation - Recent Pipeline Updates 55
Bone Marrow Transplantation - Dormant Projects 65
Bone Marrow Transplantation - Discontinued Products 66
Bone Marrow Transplantation - Product Development Milestones 67
Featured News & Press Releases 67
Nov 17, 2015: Pluristem to Present New Data on PLX-R18 at American Society of Hematologys Annual
Meeting 67
May 06, 2015: Pluristem Granted European Patent for Use of Cells to Help Treat Damaged Bone Marrow
67
Mar 24, 2015: Pluristem Announces Key Strategic Objectives for Development of PLX-R18 in
Hematopoietic Indications 68
Mar 03, 2015: Pluristem and Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells
Improve Bone Marrow Transplantation 68
Dec 04, 2014: Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD
Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes 70
Nov 13, 2014: Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to
Commence Human Clinical Trials 70
Oct 27, 2014: Case Western Reserve University to Study Pluristems PLX-RAD Cells in Umbilical Cord
Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases 71
May 07, 2013: Pluristem Develops PLX-RAD Cells For Use In Hematology 72
Sep 05, 2012: Pluristem Therapeutics Announces Successfully Treatment Of Third Critically Ill Patient
With PLX Cells Under Compassionate Use 72
May 09, 2012: Pluristem's PLX Cells Saves Life Of Child After Bone Marrow Transplantation Failure 73
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75

Expert Panel Validation 75

Contact Us 75
Disclaimer 76"

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173356/bone-marrowtransplantation-pipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects